Whalesbook
Regulatory Uncertainty in India's E-Pharmacy Sector
India's online pharmacy sector continues to navigate a complex legal and regulatory landscape. Despite significant growth and high valuations, the industry operates under older rules. The proposed Draft Drugs and Cosmetics (Amendment) Rules of 2018, which aimed to provide a clear framework for online drug sales with rules on registration and prescription verification, have not yet been finalized. This leaves digital platforms operating as intermediaries, largely governed by the Information Technology Act.
Retail Chemists Raise Concerns
Union Minister G Kishan Reddy's recent call for a review comes amid widespread discontent among traditional retail pharmacies. The All India Organisation of Chemists and Druggists (AIOCD), representing over 1.2 million chemists, argues that e-pharmacies create an unfair market. Their concerns, highlighted by a nationwide strike on May 20, 2026, include aggressive discounting by corporate e-pharmacies, which they view as predatory. Furthermore, they are concerned about the potential for fake prescriptions and the sale of certain antibiotics without proper verification, which could worsen antimicrobial resistance.
Risks for Digital Platforms
Major e-pharmacy players, including Tata 1mg, Reliance-owned Netmeds, and Apollo 24/7, face significant operational risks due to this lack of clear regulation. While these companies have expanded into telemedicine and diagnostics, their reliance on the current legal structure is unstable. Various High Courts have prompted the government to establish a formal policy. Without specific sector guidelines, a sudden shift in enforcement of existing pharmaceutical laws could force these digital businesses to undertake costly and disruptive changes.
Future Scrutiny and Market Outlook
The e-pharmacy sector can expect increased attention on its supply chain management. As India updates its regulatory framework, replacing the 1940 Drugs and Cosmetics Act, new requirements for digital record-keeping and tracking systems will likely become mandatory. E-pharmacies must move past growth fueled by discounts and focus on compliance and patient safety. While the market is expected to grow substantially by 2035, investors should be aware of the risks. Future government policies could either support the digital model or impose strict operational limits, potentially impacting current profit margins.